Rafferty Asset Management
GLUE icon

Rafferty Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Rafferty Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Sell
58,755
-45,866
-44% -$867K ﹤0.01% 724
2026
Q1 		$1.72M Buy
104,621
+37,183
+55% +$711K 0.01% 641
2025
Q4 		$1.06M Buy
+67,438
New +$909K ﹤0.01% 789
2025
Q1 		– Sell
-27,698
Closed -$192K – 1100
2024
Q4 		$192K Buy
+27,698
New +$208K ﹤0.01% 1109

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rafferty Asset Management's GLUE Position: Q2 2026 in Review

Rafferty Asset Management reduced its Monte Rosa Therapeutics (GLUE) stake by 44% in Q2 2026, selling an estimated $867K and leaving 58,755 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #724.

Rafferty Asset Management first reported a position in GLUE in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.72M in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Rafferty Asset Management held 58,755 shares of Monte Rosa Therapeutics worth $1.42M as of Q2 2026.
  • Rafferty Asset Management sold 45,866 Monte Rosa Therapeutics shares in Q2 2026, an estimated $867K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #724 holding.
  • Rafferty Asset Management first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Rafferty Asset Management's Monte Rosa Therapeutics position peaked at $1.72M in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.